Clinical trials
Myeloproliferative Neoplasm clinical trials
Below are recruiting myeloproliferative neoplasm clinical trials, each written for real people, not researchers. We’re tracking 73 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07204392Recruiting
Genetic study for early-onset or familial MPN
This study explores whether certain inherited gene changes make people more likely to develop myeloproliferative neoplasms (MPNs). It is looking at patients who were diagnosed at a young age or have a family history of blood cancers, to better understand the genetic causes of these conditions.
Pavia, LombardyAges 18 years+ - NCT06138587RecruitingPhase 1
NK cell therapy after stem cell transplant for high-risk blood cancers
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
Boston, MassachusettsAges 18 years+ - NCT05521204RecruitingPhase 2
Olverembatinib for cancers with FGFR1 gene changes
This trial studies olverembatinib to treat certain blood cancers that have an FGFR1 rearrangement (a specific gene change). It’s for people whose disease is newly diagnosed, has progressed, or has come back, and who can safely take the study medicine and attend follow-up visits.
Suzhou, JiangsuAges Any age - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT02760238Recruiting
Myeloproliferative Neoplasms patient registry study
This is a research registry for people who have certain blood cancers called myeloproliferative neoplasms (MPNs). It helps researchers learn about the disease over time and may help future studies find and compare patients.
Toronto, OntarioAges Any age - NCT06150157RecruitingPhase 1
Study of JNJ-88549968 for CALR-mutated blood cancers
This study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (essential thrombocythemia or myelofibrosis) that have a CALR gene mutation. It may offer a new treatment option for those who haven't responded well to other therapies.
Duarte, CaliforniaAges 18 years+ - NCT05842603Recruiting
Lifestyle program to help people with MPN move more
This pilot study tests a lifestyle and movement program for adults with certain myeloproliferative neoplasms (MPNs), aiming to improve well-being through safe exercise habits. You may be considered if you have an MPN and at least one heart-related risk factor.
Boston, MassachusettsAges 18 years+ - NCT05326919Recruiting
Study biobank for people newly diagnosed with certain blood cancers
This study follows people who are newly diagnosed (and haven’t been fully treated yet) with specific leukemia or related blood disorders to help researchers learn which treatments may work best. It may help by connecting you to a larger “precision medicine” patient group for future research.
BobignyAges Any age - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT06462664Recruiting
Monocytes and myeloproliferative neoplasms study
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
BrestAges 18 years+ - NCT04942080Recruiting
Using CALR test results to track certain blood cancers
This study looks at how much of a specific gene change (CALR) you have, and whether it helps doctors diagnose and follow people with certain blood cancers over time. It mainly involves using samples and medical data rather than testing a new drug.
AngersAges 18 years+ - NCT06059391RecruitingPhase 2
Vaccine for stem cell donors to prevent CMV
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
Duarte, CaliforniaAges 18–75 - NCT07680868Recruiting
Caris Chromoseq data collection for blood cancers
This study collects data from a special genetic test called Caris Chromoseq for people with certain blood cancers. It aims to learn more about these diseases and possibly guide better treatments.
Phoenix, ArizonaAges 18 years+ - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT05714592Recruiting
Optical genome mapping for bone marrow changes in blood cancer
This trial tests whether a special eye-based lab test called optical genome mapping can better detect new (acquired) chromosome changes in people with certain slow-growing blood cancers. It may help doctors choose the right next steps based on what’s happening in the bone marrow.
Amiens, PicardieAges 18 years+ - NCT06715267Recruiting
MPN in youth: studying disease features and complications
This study looks at young people (children, teens, and adults under 30) who have a type of blood cancer called myeloproliferative neoplasm (MPN). It aims to better understand the disease and its complications over time, with the goal of improving care.
BrestAges birth–30 years - NCT05553873Recruiting
Study links inflammation levels to outcomes in MPN patients
This study looks at inflammation-related lab markers in people with “Ph-negative” myeloproliferative neoplasms (like PV, ET, or PMF) to see how they relate to outcomes and response to treatment. It’s observational, meaning it gathers information from medical records without testing a new treatment.
BariAges 18–99 - NCT07419178Recruiting
New scan test for scarring in blood cancers
This study tests a new way to detect scar tissue in the bone marrow using a special scan and blood test. It might help doctors see how your disease is changing without needing a bone marrow biopsy.
Parma, ItalyAges 18 years+ - NCT07410247Recruiting
Registry for children with MPN blood cancers
This study tracks children and teens with certain rare blood cancers called myeloproliferative neoplasms (MPNs). By collecting information from many patients, doctors hope to better understand these conditions and improve care for young people.
Erlangen, BavariaAges birth–17 years - NCT05835466RecruitingPhase 2
Reparixin for myelofibrosis patients who can’t use JAK inhibitors
This Phase 2 study tests reparixin, a drug aimed at reducing problems caused by myelofibrosis (bone marrow scarring). It focuses on people who have intermediate-2 or higher risk myelofibrosis and either didn’t respond to JAK inhibitor treatment or can’t tolerate it, to see if symptoms and disease markers improve.
Tampa, FloridaAges 18 years+ - NCT03589729RecruitingPhase 2
Dexrazoxane to help protect the heart during blood-cancer chemo
This Phase 2 study tests dexrazoxane, a heart-protecting medicine, to reduce heart side effects from chemotherapy in people with certain blood cancers. If you qualify, you would receive dexrazoxane along with chemotherapy, and the team will monitor your heart function closely.
Houston, TexasAges 12 years+ - NCT06892223RecruitingPhase 2
Anti-NKG2A antibody for leukemia or MDS after half-matched transplant
This trial tests a drug that targets NKG2A, a protein that may help prevent cancer cells from hiding from the immune system. It is for people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related conditions who have already received a half-matched stem cell transplant (haploidentical transplant) with a specific anti-rejection drug plan.
Genova, GENOVAAges 18–99 - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloproliferative neoplasm?
- Yes. Clin2 currently lists 73 recruiting myeloproliferative neoplasm studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloproliferative neoplasm trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloproliferative neoplasm trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Myelodysplastic/Myeloproliferative Neoplasm
- Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Refractory Myelodysplastic/Myeloproliferative Neoplasm
- Malignant Solid Neoplasm
- Malignant Neoplasm
- Advanced Malignant Solid Neoplasm
- Hematopoietic and Lymphatic System Neoplasm
- Metastatic Malignant Solid Neoplasm
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.